Home › Blood Cancers › Massachusetts › Boston
Blood Cancers clinical trials in Boston, MA
25 studies for Blood Cancers are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Recruiting
- Massachusetts General Hospital, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
RecruitingObservational study
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Recruiting
- Dana Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Beth Israel Deaconess Medical Center, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
RecruitingObservational studyHealthy volunteers welcome
- Dana Farber Cancer Institute, Boston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
RecruitingPhase 2
- Brigham and Women's Hospital, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RecruitingHealthy volunteers welcome
- Dana-Farber Cancer Institute, Boston
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
RecruitingPhase 3
- Tufts Medical Center, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
IVIG for Infection Prevention After CAR-T-Cell Therapy
RecruitingPhase 2
- Massachusetts General Hospital Cancer Center, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RecruitingObservational study
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation
Recruiting
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Recruiting
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecruitingPhase 1
- Massachusetts General Hospital, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RecruitingPhase 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Recruiting
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Recruiting
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RecruitingPhase 1
- Dana-Farber Cancer Institute, Boston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RecruitingPhase 1
- Dana-Farber Cancer Institute, Boston
Blood Cancers trials in other cities
- Houston, TX46 studies
- New York City, NY26 studies
- Washington, DC19 studies
- Baltimore, MD18 studies
- Seattle, WA18 studies
- Los Angeles, CA17 studies
- Durham, NC16 studies
- Chicago, IL15 studies
- Philadelphia, PA14 studies
- Atlanta, GA13 studies
- Nashville, TN13 studies
- Edison, NJ13 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.